Thursday, October 14, 2021 6:56:36 PM
The price action nonsense was 100% on track
right to the target I forecasted with the Fib math nonsense a day or two earlier. The Fibonacci math is such nonsense that the price actually followed the math track precisely along the math pattern,precisely to the forecasted target.
I love the Fibonacci nonsense. and I hope my chart work does help people to "see" the price action technical track patterns. It doesnt alyways hit precise bullseyes like it has done this week, but most of the time 80-90% is a good road map to examine, and thats why I draw my charts with these tools and have learned the Fibonacci language for technical pattern watching.
Here's what my chart looks like now.
Target down could hit these lines of support. I'd like to see 17.60 hold now, but 17.50 and 17.40 area look ok. below 17.40 starts to lose more of the rally momentum.
The upward targets are looking at 18.60-70 area and the key to achieve the next bullish rally target is 19.30 area,then 20.30-20.50-20.70 area on the technical nonsense chart.
A cautious bias ,which I always have is watching for resistance to cap rallies,and the 18.60-19.25 area to struggle, and if it gets to 20 area,and the S+P starts to show selling pressure along some bad global news, my caution would be to prepare for market collapse trouble, at some point, AVXL could see its last rally for a while, maybe it could be this current rally,and how high it climbs now is the guess to decide where to lighten some trading shares and raise more cash. I'm watching the 19-20-21 area for that resistance and timing. My timing could prove wrong, of course. but the TA price action has been strongly following the Fibonacci nonsense track patterns,so I'll stay the course in my analysis of what I'm seeing.
The last thing I ever want to do is sell AVXL shares too soon and miss out on extra profits. But I do think this season and this month is a time for great caution.
Thats why I want to post the S+P chart as well as AVXL.
Fib target nonsense bullseyes
right to the target I forecasted with the Fib math nonsense a day or two earlier. The Fibonacci math is such nonsense that the price actually followed the math track precisely along the math pattern,precisely to the forecasted target.
I love the Fibonacci nonsense. and I hope my chart work does help people to "see" the price action technical track patterns. It doesnt alyways hit precise bullseyes like it has done this week, but most of the time 80-90% is a good road map to examine, and thats why I draw my charts with these tools and have learned the Fibonacci language for technical pattern watching.
Here's what my chart looks like now.
Target down could hit these lines of support. I'd like to see 17.60 hold now, but 17.50 and 17.40 area look ok. below 17.40 starts to lose more of the rally momentum.
The upward targets are looking at 18.60-70 area and the key to achieve the next bullish rally target is 19.30 area,then 20.30-20.50-20.70 area on the technical nonsense chart.
A cautious bias ,which I always have is watching for resistance to cap rallies,and the 18.60-19.25 area to struggle, and if it gets to 20 area,and the S+P starts to show selling pressure along some bad global news, my caution would be to prepare for market collapse trouble, at some point, AVXL could see its last rally for a while, maybe it could be this current rally,and how high it climbs now is the guess to decide where to lighten some trading shares and raise more cash. I'm watching the 19-20-21 area for that resistance and timing. My timing could prove wrong, of course. but the TA price action has been strongly following the Fibonacci nonsense track patterns,so I'll stay the course in my analysis of what I'm seeing.
The last thing I ever want to do is sell AVXL shares too soon and miss out on extra profits. But I do think this season and this month is a time for great caution.
Thats why I want to post the S+P chart as well as AVXL.
Fib target nonsense bullseyes
Recent AVXL News
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
